Our Vision is to Improve Yours

NASDAQ: EYEN

A public eye care company with topical ophthalmic therapies that are easier to use and easier to live with.
The Optejet® is the only FDA-approved ophthalmic spray alternative to eye drops.

Pipeline

Our pipeline candidates are designed to address the issues of conventional eye drop bottles delivering the appropriate dose and a better patient experience. More

MicroPine

Eyenovia’s lead pipeline candidate is MicroPine for the prevention of myopia progression in children. If approved, MicroPine will be the first drug-device combination product for this condition. The Optejet could enable more children to self-administer atropine. More

Latest News

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Accessibility

If you require assistance accessing this site, please contact Eyenovia at (833) 393-6684 Extension 1